Feb. 17, 2026 -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment. In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance BEA-17, Beactica's wholly ow

Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening the Company’s financial position as it advances the

Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a commercial-stage entity. The placement was led by existing investor BVF Partners and joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional investors. The company will also use the proceeds for completing its ongoing Phase III ENSURE studies of vidofludimus calcium in relapsing multiple s

Neurent Medical, a company that has created a minimally invasive solution to treat chronic rhinitis, has raised $74 million in an oversubscribed Series C round. The Galway, Ireland-based company said it will use the funding to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline. Neurent has developed Neuromark. The product uses a proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that

Financing led by Investissement Qu é bec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients MONTREAL and STRASBOURG, France and BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close of its Series B financing round totaling $32 mi

Feb. 10, 2026 -- ArrayPatch Ltd, a biotech company developing innovative microneedle-based therapeutics, today announced the first close of its €3 million seed funding round, to advance its lead program ITZ-DerMap™, a novel therapeutic designed for the treatment of onychomycosis (nail fungus). €1.6 million of the round has now been secured, led by Lakeside Capital Ltd. Additional investors included Enterprise Ireland, The Boole Investment Syndicate and DeepIE Ventures. Sean Corkery, Director at

Over the last decade-plus, China has become a booming biopharma innovator thanks in part to a big boost from its government. Now the question is, can its neighbor to the south, India, make a similar advancement? Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with help from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and bios

Feb. 3, 2026 -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM™ Antimicrobial Technology platform to minimize wound care complications. "The strategic investment from BioLab Holdings marks a pivo

Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline. The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova Partners, Sphera Healthcare, and Coastlands Capital. Settlement of the offering is expected around 30 January 2026, s

Jan. 30, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm, today announced the closing of a financing round in Epikast, a premier provider of technology-enabled commercial and clinical services for the biopharmaceutical industry. This transaction marks the first investment from Kos' inaugural fund, which is focused on a broad range of investment stages, including the seeding and scaling of high-impact life sciences platforms. Kos led the round with significant